Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03101085Phase 1Completed

S-Equol in Alzheimer's Disease 2 Trial

Role: collaborator

NCT00962390Phase 2Completed

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

Role: lead

NCT02142777Phase 1Completed

S-Equol in Alzheimer's Disease (SEAD) Trial

Role: collaborator

NCT00962585Phase 2Completed

Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

Role: lead

NCT00998920Phase 1Completed

Multi-Dose Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

Role: lead

NCT00787007Phase 1Completed

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

Role: lead

All 6 trials loaded